课题基金 / 基金详情

Lipoteichoic acid : Augmentation of the therapeutic effect of radiation and 5-fluorouracil in head and neck cancer

Lipoteichoic acid : Augmentation of the therapeutic effect of radiation and 5-fluorouracil in head and neck cancer
脂磷壁酸:增强放射线和5-氟尿嘧啶对头颈癌的治疗效果
批准号:
09557170
负责人:
SATO Mitsunobu
金额:
$7.55万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1999

项目摘要

项目成果

SATO Mitsunobu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Interferon (IFN-γ-inducing molecule (OK-LTA) has been purified from the streptococcal agent OK-432, by an affinity chromatography on CNBr-activated Sepharose 4B bound the TS-2 monoclonal antibody which neutralizes IFN-γ-inducing activity of OK-432. The OK-LTA is a glyco-conjugate with a certain structure of lipoteichoic acids. OK-LTA carried striking antitumor activity in vivo and in vitro.2. OK-LTA induced several cytokines such as IFN-α,-β,-γ, tumor necrosis factor(TNF)-α,-β, interleukin(IL)-2, IL-6, IL-12, IL-18, as well as natural killer(NK) and lymphokine-activated killer(LAK) activities on human peripheral blood mononuclear cells(PBMC).3. Nude mice bearing human head and neck cancer cells were treated with X-ray(10Gy), 5-FU(40mg/Kg), and/or OK-LTA. It was sugested that the anti-tumor effect of 5-FU were enhanced by OK-LTA.4. The negative liposome kit (egg lecithin : dicethyphosphate : cholesterol = 7 : 2 : 1, molar ratio) was used to improve the delivery of the agent (OK-LTA) to effector cells and to increase its therapeutic effect. The significantly lesser amounts of OK-LTA encapsulated into liposomes (Lipo-OK-LTA) than OK-LTA alone (1/100 or less amounts of OK-LTA alone) were required to induce IFN-γ, TNF-α,-β, IL-1β, NK, and LAK activities by human PBMC as well as by mouse spleen cells (MSC). Furthermore, higher levels of these activities were detected in PBMC and MSC treated with Lipo-OK-LTA than with OK-LTA alone.5. All of these activities induced by Lipo-OK-LTA were almost completely neutralized by anti-asialo-GM1 antibody and complement (P<0.001). In in vivo experiments, it was clearly indicated that Lipo-OK-LTA significantly accelerated anti-tumor ability of X-ray and 5-FU.
期刊论文(88)
专著(0)
科研奖励(0)
会议论文
Azuma M: "Enhancement of bFGF export associated with malignant progression of human salivary gland cell clones."Int J Cancer. 71(5). 891-896 (1997)
Azuma M:“bFGF 输出的增强与人类唾液腺细胞克隆的恶性进展相关。”Int J Cancer。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hoque MO: "Significant correlation between matrix metalloproteinase activity and tumor necrosis factor-αin salivary extravasation mucoceles."J Oral Pathol Med. 27(1). 30-33 (1998)
Hoque MO:“唾液外渗粘液囊肿中基质金属蛋白酶活性与肿瘤坏死因子-α 之间的显着相关性。”J Oral Pathol Med 27(1)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Azuma M: "TGF-β1 inhibits NF-kB activity through induction of IkB-αexpression in human salivary gland cells."Exp Cell Res. 250(1). 213-222 (1999)
Azuma M:“TGF-β1 通过诱导人唾液腺细胞中的 IkB-α 表达来抑制 NF-kB 活性。”Exp Cell Res 250(1)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
79
    Syntheses of apatite via Ca complexes of amino acids involved innon-collagen protein
    • 批准号:
      22550183
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2010
    • 负责人:
      SATO Mitsunobu
    • 依托单位:
    Toll-like receptor 4 signaling : Enhancement of therapeutic effect of anti-cancer drugs and radiation in oral Cancer
    • 批准号:
      14207090
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $32.28万
    • 财政年份:
      2002
    • 负责人:
      SATO Mitsunobu
    • 依托单位:
    Development of the therapy for oral cancer by transduction of iNOS gene in combination with radiotherapy
    • 批准号:
      12557176
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $6.66万
    • 财政年份:
      2000
    • 负责人:
      SATO Mitsunobu
    • 依托单位:
    Study on differentiation and apoptosis-inducing therapy for head and neck cancer by vesnarinone
    • 批准号:
      10307051
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $25.81万
    • 财政年份:
      1998
    • 负责人:
      SATO Mitsunobu
    • 依托单位:
    国内基金
    海外基金
    OSMI-4靶向O-糖基化调控PD-L1联合裂解OK-432协同治疗不完全消融后残存肝癌的机制研究
    • 批准号:
      JCZRLH202600261
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    OK-432联合PD-1单抗治疗肝癌射频消融后残存和远处转移瘤的机制及疗效研究
    • 批准号:
      82072041
    • 项目类别:
      面上项目
    • 资助金额:
      55.0万元
    • 批准年份:
      2020
    • 负责人:
      阚雪锋
    • 依托单位:
    OK-432和西地那非治疗儿童淋巴管畸形机制的探讨
    • 批准号:
      81300238
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      23.0万元
    • 批准年份:
      2013
    • 负责人:
      侯昉
    • 依托单位:
    OK-432肿瘤疫苗抗肿瘤作用的信号传导机制
    • 批准号:
      81141091
    • 项目类别:
      专项基金项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2011
    • 负责人:
      李宪起
    • 依托单位: